TY - JOUR
T1 - Nutraceuticals as potential therapeutics for vesicant-induced pulmonary fibrosis
AU - Businaro, Rita
AU - Maggi, Elisa
AU - Armeli, Federica
AU - Murray, Alexa
AU - Laskin, Debra L.
N1 - Funding Information:
This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant/award number: U54AR055073) and the National Institute of Environmental Health Sciences (grant/award numbers: P30ES005022, R01ES004738).
Publisher Copyright:
© 2020 New York Academy of Sciences.
PY - 2020/11/17
Y1 - 2020/11/17
N2 - Exposure to vesicants, including sulfur mustard and nitrogen mustard, causes damage to the epithelia of the respiratory tract and the lung. With time, this progresses to chronic disease, most notably, pulmonary fibrosis. The pathogenic process involves persistent inflammation and the release of cytotoxic oxidants, cytokines, chemokines, and profibrotic growth factors, which leads to the collapse of lung architecture, with fibrotic involution of the lung parenchyma. At present, there are no effective treatments available to combat this pathological process. Recently, much interest has focused on nutraceuticals, substances derived from plants, herbs, and fruits, that exert pleiotropic effects on inflammatory cells and parenchymal cells that may be useful in reducing fibrogenesis. Some promising results have been obtained with nutraceuticals in experimental animal models of inflammation-driven fibrosis. This review summarizes the current knowledge on the putative preventive/therapeutic efficacy of nutraceuticals in progressive pulmonary fibrosis, with a focus on their activity against inflammatory reactions and profibrotic cell differentiation.
AB - Exposure to vesicants, including sulfur mustard and nitrogen mustard, causes damage to the epithelia of the respiratory tract and the lung. With time, this progresses to chronic disease, most notably, pulmonary fibrosis. The pathogenic process involves persistent inflammation and the release of cytotoxic oxidants, cytokines, chemokines, and profibrotic growth factors, which leads to the collapse of lung architecture, with fibrotic involution of the lung parenchyma. At present, there are no effective treatments available to combat this pathological process. Recently, much interest has focused on nutraceuticals, substances derived from plants, herbs, and fruits, that exert pleiotropic effects on inflammatory cells and parenchymal cells that may be useful in reducing fibrogenesis. Some promising results have been obtained with nutraceuticals in experimental animal models of inflammation-driven fibrosis. This review summarizes the current knowledge on the putative preventive/therapeutic efficacy of nutraceuticals in progressive pulmonary fibrosis, with a focus on their activity against inflammatory reactions and profibrotic cell differentiation.
KW - epithelial–mesenchymal transition
KW - inflammation
KW - mustards
KW - nutraceuticals
KW - oxidative stress
KW - pulmonary fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85097112497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097112497&partnerID=8YFLogxK
U2 - 10.1111/nyas.14442
DO - 10.1111/nyas.14442
M3 - Review article
C2 - 32725637
AN - SCOPUS:85097112497
SN - 0077-8923
VL - 1480
SP - 5
EP - 13
JO - Annals of the New York Academy of Sciences
JF - Annals of the New York Academy of Sciences
IS - 1
ER -